WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 ...
21hon MSN
Moderna's cancer vaccine is incredibly promising, but this could be a major obstacle to its success
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.
Moderna (MRNA) will advance its investigational mRNA-1469 vaccine candidate against Bundibugyo ebolavirus toward a phase 2/3 efficacy study in the Democratic Republic of the Congo ...
Moderna shares rose 8.8% to $248.63 after mRNA-1469 advanced toward Phase 2/3 trials in the DRC targeting Bundibugyo ...
Tech Times on MSN
Czech COVID Vaccine Coverage 2027: State Exits Market, Insurer Reimbursement Not Guaranteed
Czech COVID vaccine coverage 2027: Health Minister Adam Vojtech has announced the Czech state will exit pandemic-era procurement on January 1, cutting the vaccination budget by 484 million CZK.
Initial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory multiple ...
Explore October's biggest pharma stories, from Regeneron’s muscle-loss trial to Moderna’s melanoma vaccine and the Nobel Prize for optogenetics.
Vaccination provides the best protection against influenza. Several safe and effective vaccines are available this season.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results